NYSE: ABTAbbott Laboratories Stock Forecast, Predictions & Price Target
Analyst price target for ABT
Based on 12 analysts offering 12 month price targets for Abbott Laboratories.
Min Forecast
$102.00-5.87%
Avg Forecast
$112.83+4.13%
Max Forecast
$125.00+15.36%
Should I buy or sell ABT stock?
Strong Buy
Strong Buy
11 analysts 73.33%
Buy
1 analysts 6.67%
Hold
3 analysts 20.00%
Sell
0 analysts 0.00%
Strong Sell
0 analysts 0.00%
Forecast return on equity
Is ABT forecast to generate an efficient return?
Company
28.46%
Industry
31.75%
Market
-1.56%
ABT's Return on Equity is forecast to be high in 4 years (28.46%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast
Forecast return on assets
Is ABT forecast to generate an efficient return on assets?
Company
12.74%
Industry
13.91%
Market
11.47%
ABT is forecast to generate lower Return on Assets (12.74%) than the US Medical Devices industry average (13.91%)
Forecast
ABT earnings per share forecast
What is ABT's earnings per share in the next 3 years based on estimates from 10 analysts?
Avg 1 year Forecast
$3.30+88.69%
Avg 2 year Forecast
$3.99+127.77%
Avg 3 year Forecast
$4.37+149.81%
ABT's earnings are forecast to grow at an exceptional rate of 36.45% per year
Forecast
ABT revenue forecast
What is ABT's revenue in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$33.0B+4.99%
Avg 2 year Forecast
$36.7B+16.84%
Avg 3 year Forecast
$38.7B+23.09%
ABT's revenue is forecast to grow at a rate of 7.48% per year, which is not exceptional
Forecast
ABT earnings growth forecast
How is ABT forecast to perform vs Medical Devices companies and vs the US market?
Company
36.45%
Industry
34.50%
Market
14.71%
ABT's earnings are forecast to grow faster (36.45% per year) than the US Medical Devices industry average (34.50%)
Forecast
ABT's earnings are forecast to grow faster (36.45% per year) than the US market average (14.71%)
Forecast
ABT revenue growth forecast
How is ABT forecast to perform vs Medical Devices companies and vs the US market?
Company
7.48%
Industry
8.70%
Market
5.62%
ABT's revenues are forecast to grow slower (7.48% per year) than the US Medical Devices industry average (8.70%)
Forecast
ABT's revenues are forecast to grow faster (7.48% per year) than the US market average (5.62%)
Forecast
Abbott Laboratories Stock Forecast FAQ
Is Abbott Laboratories Stock a good buy in 2020, according to Wall Street analysts?
The consensus among 15 Wall Street analysts covering (NYSE: ABT) stock is to Strong Buy ABT stock.
Out of 15 analysts, 11 (73.33%) are recommending ABT as a Strong Buy, 1 (6.67%) are recommending ABT as a Buy, 3 (20.00%) are recommending ABT as a Hold, 0 (0.00%) are recommending ABT as a Sell, and 0 (0.00%) are recommending ABT as a Strong Sell.
What is ABT's Price Target?
According to 12 Wall Street analysts that have issued a 1 year ABT price target, the average ABT price target is $112.83, with the highest ABT stock price forecast at $125.00 and the lowest ABT stock price forecast at $102.00.
On average, Wall Street analysts predict that Abbott Laboratories's share price could reach $112.83 by Oct 15, 2021. The average Abbott Laboratories stock price prediction forecasts a potential upside of 4.13% from the current ABT share price of $108.36.
What is ABT's earnings growth forecast for 2020-2022?
(NYSE: ABT) Abbott Laboratories's forecast annual earnings growth rate of 36.45% is forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 34.50%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 14.71%.
Abbott Laboratories's earnings in 2020 is $3,110,000,000.On average, 10 Wall Street analysts forecast ABT's earnings for 2020 to be $5,840,727,266, with the lowest ABT earnings forecast at $5,748,747,310, and the highest ABT earnings forecast at $6,208,647,094. On average, 10 Wall Street analysts forecast ABT's earnings for 2021 to be $7,050,617,469, with the lowest ABT earnings forecast at $6,544,727,706, and the highest ABT earnings forecast at $7,995,180,874.
In 2022, ABT is forecast to generate $7,732,861,112 in earnings, with the lowest earnings forecast at $7,110,758,211 and the highest earnings forecast at $8,808,849,723.
What is ABT's revenue growth forecast for 2020-2022?
(NYSE: ABT) Abbott Laboratories's forecast annual revenue growth rate of 7.48% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.70%, and while it is forecast to beat the US market's average forecast revenue growth rate of 5.62%.
Abbott Laboratories's revenue in 2020 is $31,444,000,000.On average, 7 Wall Street analysts forecast ABT's revenue for 2020 to be $58,395,982,124,804, with the lowest ABT revenue forecast at $57,683,814,926,186, and the highest ABT revenue forecast at $59,734,490,377,978. On average, 7 Wall Street analysts forecast ABT's revenue for 2021 to be $64,988,111,348,050, with the lowest ABT revenue forecast at $62,397,787,719,976, and the highest ABT revenue forecast at $68,106,028,471,511.
In 2022, ABT is forecast to generate $68,463,340,533,899 in revenue, with the lowest revenue forecast at $65,326,995,579,832 and the highest revenue forecast at $70,934,235,263,252.
What is ABT's Earnings Per Share (EPS) forecast for 2020-2022?
(NYSE: ABT) Abbott Laboratories's current Earnings Per Share (EPS) is $1.75. On average, analysts forecast that ABT's EPS will be $3.30 for 2020, with the lowest EPS forecast at $3.25, and the highest EPS forecast at $3.51. On average, analysts forecast that ABT's EPS will be $3.99 for 2021, with the lowest EPS forecast at $3.70, and the highest EPS forecast at $4.52. In 2022, ABT's EPS is forecast to hit $4.37 (min: $4.02, max: $4.98).
What is ABT's forecast return on equity (ROE) for 2020-2023?
(NYSE: ABT) forecast ROE is 28.46%, which is considered strong.
What is ABT's forecast return on assets (ROA) for 2020-2023?
(NYSE: ABT) forecast ROA is 12.74%, which is lower than the forecast US Medical Devices industry average of 13.91%.
©2020 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
